Table 4.
BNT162b2 vaccine effectiveness against COVID-19-associated hospitalization for acute respiratory infection among adults with a SARS-CoV-2 test.
| Pre/Delta Era (2 May 2020–19 December 2021) | Omicron Era (20 December 2021–31 January 2023) | Overall | ||||
|---|---|---|---|---|---|---|
| All Participants | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) |
| Primary Series | ||||||
| Overall | 79.6 (67.4, 87.2) | 80.8 (67.6, 88.7) | 19.6 (−9.6, 41.0) | 24.5 (−4.5, 45.4) | 59.7 (48.4, 68.6) | 58.5 (46.0, 68.1) |
| <6 months since completion | 84.1 (71.8, 91.0) | 84.4 (70.7, 91.6) | −12.2 (−87.3, 32.8) | −8.9 (−90.0, 37.6) | 55.3 (34.8, 69.3) | 54.7 (32.4, 69.6) |
| ≥6 months since completion | 66.9 (30.8, 84.2) | 74.7 (44.5, 88.4) | 27.9 (−1.5, 48.8) | 34.0 (5.6, 53.8) | 61.9 (49.0, 71.6) | 61.5 (47.7, 71.7) |
| Booster + (Primary series + ≥1 booster) | ||||||
| Overall | 86.6 (−30.1, 98.6) | 89.9 (0.1, 99.0) | 50.9 (30.0, 65.5) | 60.9 (42.0, 73.6) | 76.4 (67.5, 82.9) | 78.9 (70.0, 85.1) |
| <6 months since completion | 86.6 (−30.1, 98.6) | 89.9 (0.1, 99.0) | 55.8 (30.4, 71.9) | 64.1 (41.4, 78.0) | 78.6 (67.3, 86.0) | 79.3 (67.4, 86.8) |
| ≥6 months since completion | -- | -- | 44.5 (11.2, 65.3) | 55.7 (25.9, 73.5) | 73.4 (58.5, 83.1) | 77.8 (64.2, 86.2) |
| Pre/Delta Era | Omicron Era | Overall | ||||
| African American/Black race (Any) | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) |
| Primary Series | ||||||
| Overall | 75.1 (55.7, 86.0) | 75.1 (53.6, 86.7) | 35.9 (4.3, 57.0) | 39.6 (8.6, 60.1) | 65.2 (52.3, 74.6) | 63.8 (49.8, 74.0) |
| <6 months since completion | 79.7 (58.7, 90.0) | 79.2 (55.4, 90.3) | −2.7 (−90.7, 44.7) | 1.9 (−85.7, 49.3) | 53.6 (26.4, 70.8) | 48.9 (17.1, 68.5) |
| ≥6 months since completion | 64.6 (13.7, 85.4) | 69.9 (23.9, 88.1) | 47.7 (16.7, 67.2) | 50.7 (20.8, 69.4) | 70.8 (56.9, 80.3) | 70.6 (56.1, 80.3) |
| Booster + (Primary series + ≥1 booster) | ||||||
| Overall | - | - | 60.8 (36.1, 75.9) | 68.5 (46.5, 81.5) | 82.4 (72.2, 88.8) | 83.4 (73.1, 89.8) |
| <6 months since completion | - | - | 71.6 (44.3, 85.5) | 75.8 (50.8, 88.1) | 87.4 (75.9, 93.4) | 86.9 (74.4, 93.3) |
| ≥6 months since completion | - | - | 43.9 (−6.3, 70.4) | 59.5 (19.7, 79.6) | 74.2 (52.1, 86.0) | 78.9 (60.0, 88.9) |
| Not-African American/Black race | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) | Unadjusted (95% CI) | Adjusted (95% CI) |
| Primary Series | ||||||
| Overall | 84.7 (64.8, 93.4) | 91.0 (75.0, 96.8) | −11.3 (−85.1, 33.1) | −14.8 (−95.1, 32.4) | 46.9 (19.9, 64.8) | 48.8 (13.0, 63.7) |
| <6 months since completion | 88.4 (68.8, 95.7) | 93.2 (77.9, 97.9) | −40.0 (−244.0, 45.5) | −38.1 (−275.7, 49.3) | 56.2 (15.7, 77.2) | 52.7 (6.5, 76.0) |
| ≥6 months since completion | 70.5 (−12.1, 92.2) | 85.4 (32.6, 96.8) | −6.3 (−82.1, 37.9) | −6.5 (−86.2, 39.0) | 42.4 (8.5, 63.7) | 40.1 (2.3, 63.3) |
| Booster + (Primary series + ≥1 booster) | ||||||
| Overall | - | - | 36.9 (−8.6, 63.3) | 48.1 (5.9, 71.3) | 65.3 (44.0, 78.5) | 71.4 (51.4, 83.2) |
| <6 months since completion | - | - | 30.0 (−35.2, 63.7) | 42.6 (−15.9, 71.5) | 60.6 (28.2, 78.3) | 65.2 (33.6, 81.7) |
| ≥6 months since completion | - | - | 44.1 (−13.8, 72.5) | 51.2 (−6.2, 77.6) | 70.3 (42.1, 84.7) | 76.8 (52.4, 88.7) |